<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886366</url>
  </required_header>
  <id_info>
    <org_study_id>D1920C00001</org_study_id>
    <nct_id>NCT00886366</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients</brief_title>
  <official_title>A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD6714 in Healthy Male Volunteers and Male Type II Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and tolerability of AZD6714 after single
      ascending oral doses in healthy male subjects and type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part A reached a predefined stopping criteria. Relevant doses for part B could not be
    established based on A and subsequently study was stopped.
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG)</measure>
    <time_frame>AEs will be collected during the whole study period (1-3 months). The other variables will be measured repeatedly during 24 hours on the study day sessions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables (P-Glucose, S-Insulin and C-peptide)</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6714</intervention_name>
    <description>Oral single doses a-h suspension</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral single doses suspension</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6714</intervention_name>
    <description>Oral single doses a-d suspension</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6714</intervention_name>
    <description>Oral single doses d and g suspension</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A,Healthy male subjects, aged between ≥20 and ≤40 years.

          -  Part B,Male T2DM patients, aged between ≥20 and ≤65 years. Treatment with metformin as
             single therapy for T2DM for at least 30 days prior to enrollment

        Exclusion Criteria:

          -  Part A,Clin sign illness or clin relevant trauma, as judged by the investigator,
             within 2 weeks before the first administration of the IP.

          -  Part A Clin sign abnormalities in clinical chemistry, haematology, or urinalysis
             results as judged by the investigator

          -  Part B, History of ischemic heart disease, symptomatic heart failure, stroke,
             transitory ischemic attack or symptomatic peripheral vascular disease.

          -  Any clinically significant abnormality identified on physical examination, laboratory
             tests or ECG, which in the judgment of the investigator would compromise the patient's
             safety or successful participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klas Malmberg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Hartford</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPU Sahlgrenska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>December 6, 2010</last_update_submitted>
  <last_update_submitted_qc>December 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Klas Malmberg, MD, PhD, Prof. Medical Science Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Type II Diabetes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

